A phase II study of gemcitabine, oxaliplatin and bevacizumab followed by 5-fluorouracil [fluorouracil], oxaliplatin, bevacizumab and radiotherapy in patients with locally advanced pancreatic cancer

Trial Profile

A phase II study of gemcitabine, oxaliplatin and bevacizumab followed by 5-fluorouracil [fluorouracil], oxaliplatin, bevacizumab and radiotherapy in patients with locally advanced pancreatic cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Bevacizumab; Fluorouracil; Gemcitabine; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jan 2017 Planned primary completion date changed from 1 Dec 2009 to 1 Dec 2017.
    • 24 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top